Streamlining Development and Approval Processes for 505(B)(2) NDAs

Sanjay Sehgal, Ph.D.
Managing Director
Aexelar Regulatory Experts, Inc.
www.aexelar.com

Sept. 5, 2013
Disclaimer

The information contained in this presentation are the views and understanding of the author, Sanjay Sehgal, and are provided in a scientific discussion with the understanding that Aexelar Inc. or any health authority makes no warranties, either expressed or implied, concerning the accuracy, completeness, reliability, or suitability of this information.
Drug Development, Review and Approval Processes

Developing a new medicine takes an average of 10–15 years.

- **Drug Discovery**: 5,000–10,000 compounds, 3–6 years
- **Preclinical**: 250
- **Clinical Trials**
  - Phase 1: 6–7 years
  - Phase 2: 0.5–2 years
  - Phase 3: Indefinite
- **FDA Review**: One FDA-approved drug
- **Scale-up to MFG.**: 0.5–2 years
- **Post-Marketing Surveillance**: Indefinite
Pharma Industry Revenue Growth by Major Geographies* (2010 to 2020)

- **2005E**: $856bn
  - US: 308
  - EU: 205
  - EM: 154
  - Other: 188

- **2015E**: $1,081bn
  - US: 335
  - EU: 205
  - EM: 303
  - Other: 238

- **2020E**: $1,318bn
  - US: 335
  - EU: 487
  - EM: 195
  - Other: 300

*Future Pharma report by KPMG group
505(j) Abbreviated NDA

- 505(j) – Abbreviated NDA (ANDA): ANDAs are submitted for drug products in which the approval of a generic drug is based on demonstrating comparability to an innovator drug (RLD) in the US:
  - Identical in active ingredients(s)
  - Identical in dosage form
  - Identical in strength
  - Identical in route of administration
  - Identical in conditions of use, labeling, performance

- Applications are “abbreviated” as they generally do not include preclinical or clinical data to establish safety and efficacy. Instead, they need to demonstrate BE to innovator product.
505(b)(1) NDA

- 505(b)(1) - Full NDA: An application that contains complete reports of investigations of safety, effectiveness, quality of drug product:
  - Used for new chemical entities
  - Studies conducted by the innovator
  - Requires complete reporting of
    - Non-clinical pharmacology/toxicology
    - Clinical pharmacology
    - Clinical investigations proving safety and efficacy
    - Quality (Chemistry, manufacturing, and controls)
505(b)(2) NDA

- 505(b)(2): Intended to encourage innovation in drug development without requiring duplicative studies (safety, efficacy) of previously known information (21CFR314.54)

- Applicant must include reports of safety and effectiveness where at least some of the information required for approval is from studies “not conducted by or for the applicant/ sponsor, and for which the applicant has not obtained a right of reference”
  - *Not a completely new product*
  - BE to a previously approved product not relevant/required
  - Documents previously reported non-clinical and clinical data
  - Approval requires clinical data to support difference(s) and/or changes to approved products.
505(b)(2) Business Drivers

- Losses in patent protection in major western markets
- $120 billion loss in product revenue during 2010-2015 due to losses in patent protection
- Significant competition and growth in generic pharmaceutical sales
- Higher regulatory hurdles, greater uncertainty for product approval
- Declining new (505b1) product approvals
- Growing safety and AE reporting requirements by regulatory agencies
505(b)(2) NDA Applications

- Change(s) that support submission of a 505(b)(2) NDA can include:
  - Dosage form (e.g. tablets to transdermal patches)
  - Strengths – higher or lower
  - Route of administration
    - oral to transdermal or iontophoretic delivery
    - Oral to IV
    - Immediate release to extended release
    - Lotion to foam, etc
  - Dosing regimen
    - Twice daily to once a day
  - API switch (new salt, ester, complex, racemate, enantiomer, combinations, etc)
Change(s) that support submission of a 505(b)(2) NDA can include (cont’d):

- Formulation changes excluding 505(j)
- Substitution of an active ingredient in a combo product
- Different active ingredient (such as a different salt)
- Indications – adding new indications
- Rx/OTC indication switches
- New combination – combining two or more actives approved individually
- Drug-device combination products
- Naturally derived or recombinant active ingredient
- Bioinequivalence.
Market Exclusivity - 505(b)(2)

- 505(b)(2) applications may be granted exclusivity under certain conditions:
  - **3 years** Waxman-Hatch exclusivity if one or more of the clinical investigation(s), other than BA/BE studies, were conducted or sponsored by the applicant - blocks approval of other pending 505b2 NDAs regardless of filing date
  - **5 years** exclusivity if the 505b2 NDA is for a new chemical entity - blocks filing of competing 505b2 NDAs.
- Orphan drug exclusivity possible
- Pediatric exclusivity possible.
Approved 505(b)(2) – 100s; Examples

- Zyrtec D (cetrizine and pseudoephedrine combo) – new combination product
- Zecuity (sumatriptan iontophoretic transdermal system) – new drug-device combination product
- Duraclin (clonoidine) – new formulation and route
- Sclerosol (sterile talc) – new molecular entity
- Children’s Advil Cold Suspension – new formulation
- Methylphenidate Oral Solution – new dosage form
- Methylphenidate Chewable Tablets – new dosage form
- Doxil (doxorubicin) Liposomal Injection – new dosage form
- Altocor (lovastatin) ER Tablets – new dosage form
- Vandazole (metronidazole) Vaginal Gel
- Forticol (calcitonin-salmon) Nasal Spray
- Luxiq Foam (betamethasone) – new delivery tech
- Canasa (mesalamine) Suppositories – new delivery tech.
<table>
<thead>
<tr>
<th>Requirement</th>
<th>505(b)(1)</th>
<th>505(b)(2)</th>
<th>505(b)(2) combo*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phases 1-3 development time</td>
<td>5–10 years</td>
<td>2–4 years</td>
<td>2–4 years</td>
</tr>
<tr>
<td>Estimated development costs</td>
<td>$800M–$2B</td>
<td>~$10M–$100M</td>
<td></td>
</tr>
<tr>
<td>Preclinical/tox data – single and repeat dose tox data (1 mo, 6 mo, 9 mo)</td>
<td>Always</td>
<td>Usually</td>
<td></td>
</tr>
<tr>
<td>Carcinogenicity studies – short, medium and long term (to 2 yrs)</td>
<td>Always</td>
<td>Usually</td>
<td></td>
</tr>
<tr>
<td>Chronic and reproductive tox (6-9 mo), genotox, local irritation, tolerance studies</td>
<td>Always</td>
<td>Usually</td>
<td></td>
</tr>
<tr>
<td>BA and comparative BA data</td>
<td>Always</td>
<td>Always</td>
<td></td>
</tr>
<tr>
<td>Pharmacokinetic data – PK, PD data</td>
<td>Always</td>
<td>Always</td>
<td></td>
</tr>
<tr>
<td>Clinical trials (Ph I-III) safety and efficacy data, bridging studies as necessary</td>
<td>Always</td>
<td>Always</td>
<td></td>
</tr>
<tr>
<td>API characterization, stability, stress-studies, photo-stability, MLT data</td>
<td>Always</td>
<td>Usually</td>
<td></td>
</tr>
<tr>
<td>Drug product stability, stress-studies, photo-stability, MLT data</td>
<td>Always</td>
<td>Always</td>
<td></td>
</tr>
<tr>
<td>FDA Meetings (preIND, EOP, preNDA)</td>
<td>Always</td>
<td>Usually helpful</td>
<td></td>
</tr>
<tr>
<td>Approval time period</td>
<td>10 mo / 6 mo</td>
<td>10 mo (std); 6 mo (priority)</td>
<td></td>
</tr>
<tr>
<td>Exclusivity</td>
<td>Always</td>
<td>3 or 5 years</td>
<td></td>
</tr>
</tbody>
</table>

*additional requirements for drug-devices
Streamlining 505(b)(2) Review and Approval Processes

- Nonclinical summary (Mod 2) and noncllin study reports (Mod 4) including the following information be reevaluated/eliminated:
  - Preclinical/tox data - single and repeat dose (1, 6, 9 mo)
  - Carcinogenicity data: short, medium, long term (2 yrs)
  - Chronic dermal tox data
  - Chronic repeat dermal tox data
  - Carcinogenicity potential and local tolerance data
  - Reproductive tox data (6-9 mo), genotox data

- API data requirements when an identical API has been approved previously:
  - characterization, stress-studies, photo-stability, MLT data
  - API stability data, impurities characterization, etc

- Hold EOPPII and pre-NDA/BLA meetings with FDA to align on submission data, bridging studies, stability data etc.

- Given the duplication of information, FDA should consider shortening the review periods to 6 months for standard and priority reviews.
Goal Is To Avoid This At All Costs

NDA Sponsor

Health Authority